Last reviewed · How we verify
UB-421
UB-421 is a monoclonal antibody that targets and blocks CD4 on T cells to modulate immune function in HIV infection.
UB-421 is a monoclonal antibody that targets and blocks CD4 on T cells to modulate immune function in HIV infection. Used for HIV-1 infection (in combination antiretroviral therapy).
At a glance
| Generic name | UB-421 |
|---|---|
| Also known as | dB4C7 mAb |
| Sponsor | United BioPharma |
| Drug class | Anti-CD4 monoclonal antibody |
| Target | CD4 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
UB-421 binds to the CD4 receptor on the surface of T cells, which is the primary entry point for HIV. By occupying this receptor, the antibody prevents HIV from attaching to and infecting CD4+ T cells. This mechanism aims to reduce viral load and preserve immune function in people living with HIV.
Approved indications
- HIV-1 infection (in combination antiretroviral therapy)
Common side effects
- Injection site reactions
- Immune activation syndrome
- Lymphocyte count changes
Key clinical trials
- A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection (PHASE2)
- A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir (PHASE2)
- To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults (PHASE3)
- Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients (PHASE1)
- UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients (PHASE2)
- UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection (PHASE3)
- A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs (PHASE2)
- The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |